Introduction
Irritable bowel syndrome (IBS) is a common condition affecting the gut and brain. Currently, there is no specific treatment for IBS. Factors like low-grade inflammation and oxidative stress may worsen symptoms, such as abdominal pain. Spirulina platensis, a type of algae, is rich in nutrients and may help reduce these issues due to its antioxidant and anti-inflammatory properties. This study aims to investigate if taking Spirulina can improve IBS symptoms.
Study Overview
This clinical trial will last 12 weeks and involve 60 adults diagnosed with IBS. Participants will be randomly assigned to take either Spirulina capsules (500 mg) or a placebo twice a day. The main goals are to see how Spirulina affects the quality of life, severity of IBS symptoms, and gut health. Additionally, we will measure antioxidant levels in the blood.
Expected Benefits
If Spirulina shows significant improvements in gut health and IBS symptoms, it could be a helpful option for managing IBS and might also lower healthcare costs.
Ethics and Results Sharing
The study has received approval from the Medical Ethics Committee in Iran. Results will be published to share findings with the medical community.
Goals and Outcomes
We aim to measure the effects of Spirulina on:
- Quality of life of IBS patients
- Severity of IBS symptoms
- Antioxidant levels in the blood
- Other relevant health markers
Using AI for Clinical Needs
We recommend selecting AI tools that can support the implementation of this research in clinical practice, helping to analyze and track results effectively.
Next Steps
Starting with pilot projects can provide insights and demonstrate the real-world effectiveness of Spirulina for IBS management. For further information about AI solutions in healthcare, please contact us:
